Evaluation of a possible synergistic effect of meglumine antimoniate with paromomycin, miltefosine or allopurinol on in vitro susceptibility of Leishmania tropica resistant isolate

Iranian Journal of Parasitology

Volumn 8, Issue 3, 2013, Pages 396-401

  Rezaei Riabi, Tahereh ^a   Sharifi, Iraj ^a   Miramin Mohammadi, Akram ^b   Khamesipour, Ali ^b   Hakimi Parizi, Maryam ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

In vitro; Leishmania tropica; Resistance; Treatment

Indexed keywords

ALLOPURINOL; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SENSITIVITY; IN VITRO STUDY; LEISHMANIA TROPICA; MACROPHAGE; MICROSCOPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROMASTIGOTE;

EID: 84884147459     PISSN: 17357020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Sayed Eh M, Anwar AE. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. J Europ Acad Dermatol Venereol. 2009; 24(3): 335-340.
2. Esfandiarpour I and Dabiri SH. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine anti-moniate: a clinical and histological study. Int J Dermatol. 2007; 46(8): 848-852.
3. Hadighi R, Boucher P, Khamesipour A, Mea-mar AR Roy G, Ouellette M, Mohebali M. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res. 2007; 101(5):1319-1322.
4. World Health Organization. Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010: World Health Organization.
5. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, Sharifi I, Khalil EAG, Bernal IDV, Antunes CMF, Kieny MP, Tann M. First generation leishmaniasis vaccines: A review of field efficacy trials. Vaccine. 2008; 26(52): 6759-6767.
6. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Mcrobiol Rev. 2006; 19(1): 111-126.
7. Hadighi R Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Ira-nian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006; 3(5): 162.
8. Pour R, Sharifi I, Kazemi B, Zarean M. Identification of non responsive isolates to Glucan-time in patients with cutaneous leishmaniasis in Bam. J Kerman Uni Med Sci. 2011; 18(2): 123-33.
9. Postigo JAR. Leishmaniasis in the world health organization eastern mediterranean region. Int J Antimicrob Agents. 2010; 36(1): 6.
10. Ouellette M, Drummelsmith J, Leprohon P, El Fadili K, Foucher A, Vergnes B, Lagara D. Drug resistance in Leishmania. Leishmania after the genome, 1st ed. Caister Academic Press, Norfolk, United Kingdom. 2008; 159-176.
11. Shokri A, Sharifi I, Khamesipour A, Nakhaee N, Fasihi Harandi M, Nosratabadi J, Hakimi Parizi M, Barati M. The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglu-mine antimoniate. Parasitol Res. 2012; 110(3):1113-7.
12. Jones PM, George AM. Multidrug resistance in parasites: ABC transporters, P-glycoproteins and molecular modeling. Int J Parasitol. 2005; 35(5): 555-566.
13. This study (project no.90/59) was supported by Kerman University of Medical Sciences.